1. Introduction {#sec1-cancers-11-01771}
===============

The spine is a very common area of metastatic disease \[[@B1-cancers-11-01771],[@B2-cancers-11-01771]\]; thus, activities of daily living and quality of life (QOL) can be markedly hampered in these patients. Spinal metastases can be categorized as stable or unstable, based on several factors such as tumor burden and location, symptomatology, and several parameters on imaging \[[@B3-cancers-11-01771]\].

Whereas stable spinal metastases are often treated with palliative radiation therapy (RT) alone, management of unstable spinal metastases (USM) represents an interdisciplinary challenge \[[@B4-cancers-11-01771],[@B5-cancers-11-01771],[@B6-cancers-11-01771],[@B7-cancers-11-01771]\]. Although surgical therapy is commonly performed, many patients with metastatic cancer are not surgical candidates for several reasons. Thus, palliative RT remains an effective treatment option for spine instability and pain \[[@B8-cancers-11-01771],[@B9-cancers-11-01771],[@B10-cancers-11-01771],[@B11-cancers-11-01771],[@B12-cancers-11-01771],[@B13-cancers-11-01771]\]. Conservative treatment often involves patient immobilization, most commonly by utilizing an orthopedic corset or with prolonged bedrest.

In order to improve QOL in cancer patients, numerous short- and long-term effects of targeted physical training measures have been reported, with practical and clinically meaningful improvements in pain and mobility \[[@B14-cancers-11-01771],[@B15-cancers-11-01771],[@B16-cancers-11-01771],[@B17-cancers-11-01771],[@B18-cancers-11-01771]\]. Specifically, additional isometric paravertebral muscle training (IPMT) may allow for strengthening paraspinal muscles and improving mobility, pain, and QOL. In a previous randomized trial for stable spine metastases, IPMT (concomitant with palliative RT) affected some of the aforementioned endpoints and did not increase the pathologic fracture rate \[[@B19-cancers-11-01771],[@B20-cancers-11-01771],[@B21-cancers-11-01771],[@B22-cancers-11-01771],[@B23-cancers-11-01771]\].

Despite these encouraging results, this regimen remains unproven for USM; as a result, most prospective trials in this population remain reluctant to implement such interventions, since IPMT in this high-risk population could lead to clinical exacerbation, including increasing the risk of pathologic fracture.

To address this knowledge gap, we conducted this exploratory randomized study, the first of its kind to date, to evaluate the feasibility of IPMT (as compared to muscle relaxation) and secondarily determine effects on pain, bone density, pathologic fracture rate, and quality of life \[[@B24-cancers-11-01771]\].

2. Materials and Methods {#sec2-cancers-11-01771}
========================

2.1. Design and Patient Population {#sec2dot1-cancers-11-01771}
----------------------------------

This exploratory randomized controlled trial (NCT02847754) was approved by the Heidelberg University Independent Ethics Committee (S-223/2016) ([Table S1](#app1-cancers-11-01771){ref-type="app"}). The goal of this study was to evaluate the feasibility of paravertebral muscle-training exercises (interventional group, INT), as compared to muscle relaxation (control group, CON), in patients with USM receiving palliative RT \[[@B24-cancers-11-01771]\]. The randomization procedure was carried out by a central office; a block randomization approach (block size of 6) was utilized.

From December 2016 to November 2018, 60 patients with histologically confirmed cancer and USM of the thoracolumbar segments were considered for this study. USM was defined based on computed tomography (CT) and/or magnetic resonance imaging (MRI) assessment based on the well-recognized Taneichi score \[[@B19-cancers-11-01771],[@B22-cancers-11-01771],[@B25-cancers-11-01771]\]. Surgical intervention to the area of USM was not allowed, mainly because the degree and extent of surgical intervention (based on tumor location) would add a major confounding factor regarding the ability to postoperatively perform paravertebral muscle training exercises in a uniform time frame. As such, this study included inoperable cases (secondary to disease extent, or medical contraindications) as well as subjects who refused surgery.

Other inclusion criteria were ages 18--80 years, Karnofsky performance score ≥ 70, ability to provide written informed consent, and an established indication for palliative RT. In order to address potential confounding by bisphosphonates or anti-RANKL agents, one of these compounds was required to be delivered if the patient was not already receiving one such agent. Exclusion criteria were previous RT or surgery to the given irradiation site, spinal cord compression according to the Bilsky score, myeloma/lymphoma histology, involvement of the cervical spine, and/or inability/refusal to complete the given exercise regimen.

2.2. Interventions {#sec2dot2-cancers-11-01771}
------------------

Complete details of IPMT (INT group) are presented elsewhere \[[@B24-cancers-11-01771]\]. Briefly, these consisted of exercises (1:1 supervised by exercise physiologists or physical therapists) performed once daily, starting on the first day of palliative RT and continuing for the entire RT period. Following RT completion, subjects continued the same exercises three times per week (corroborated by a daily log) in a home-based manner for another three months. The overall exercise regimen was estimated to take 15 min per day and consisted of isometric exercises in four positions: "all fours" (each extremity stretched separately), "plank", "swimming" (toes kept on the floor), and upright with an elastic band tightened in front of the trunk. The holding time for each position was 20 s initially, and increased from session to session when feasible. The exercises were performed without a corset.

Muscle relaxation (CON group) was also performed for an estimated 15 min (once daily) during palliative RT as above. These exercises comprised of progressive muscle relaxation for the face, arms, abdomen, and legs. The back was excluded to avoid training effects on the paravertebral muscles. Muscle relaxation was similarly performed with 1:1 supervision and could voluntarily be continued following completion of RT (corroborated by an audio CD).

Palliative RT was delivered in either three-dimensional conformal (3DCRT) or intensity-modulated (IMRT) techniques. Stereotactic body radiation therapy (SBRT) was not allowed for this study. For both techniques, the involved vertebra was treated to a dose of 20 Gy in 5 fractions or 30 Gy in 10 fractions. If IMRT was utilized, simultaneous integrated boosting (SIB) was allowed to 30 Gy for a 5-fraction regimen and 40 Gy for a 10-fraction regimen. Treatment planning was based on parameters in the Radiation Therapy Oncology Group (RTOG) 0631 study \[[@B26-cancers-11-01771]\] and QUANTEC \[[@B27-cancers-11-01771]\] recommendations. Position verification was carried out weekly before radiotherapy by kilovoltage cone-beam CT and before each fraction by orthogonal portal images being compared with digitally reconstructed radiographs from the planning CT.

2.3. Endpoints {#sec2dot3-cancers-11-01771}
--------------

Both the primary and secondary endpoint-related parameters were measured at the start of RT (t~0~), the end of RT (t~1~), three months post-RT (t~2~), and 6 months post-RT (t~3~). During therapy, the treating clinicians documented these parameters, but diaries were used to document patient-reported information subsequently.

Because performing IPMT for USM risks clinical exacerbation (including increasing the risk of pathologic fracture) the primary endpoint of this randomized investigation was feasibility, which referred to completion of the training program at three months following the end of RT. The total number of completed and aborted/canceled training units and adverse events during training was recorded.

The initial secondary endpoint was the pain score, as measured by the Visual Analog Scale (VAS). Pain level was measured by subjective patient reporting on the VAS scale with a range of 0--100. During clinical examination by the study physician, neuropathic pain was also monitored, as well as pain medication usage (opioid usage was converted into an oral morphine equivalent dose (OMED); non-opioid analgesics were also recorded).

Additional secondary endpoints were bone density and pathologic fracture rate. Bone density was assessed in the irradiated (and unirradiated) vertebral bodies by a single physician with CT imaging (Siemens Somatom Sensation Open, Siemens, Erlangen, Germany) and Syngo Osteo CT workstation in manually selected regions of interest; Hounsfield units were used for bone density measurements. Pathologic fractures were diagnosed by means of CT and/or MRI imaging and comparing to baseline imaging tests. New fractures were, by definition, not present on initial imaging, whereas progressive fractures referred to visibly increasing size and/or number of fracture gaps, dislocation of fracture fragments, or increasing sintering of the compression fracture (if applicable).

The final secondary endpoint was QOL, assessed using the EORTC QLQ BM22 questionnaire, specially designed for patients with bone metastases. This module (range 0--100) comprises of 22 items and four scales for the measurement of pain in various parts of the body (painful sites), pain characteristics (persistent pain, recurrent pain), functional impairment (occurrence of pain when performing different activities, interference with everyday activities), and psychosocial aspects (family, worries, hope) \[[@B28-cancers-11-01771]\]. Fatigue was assessed using the EORTC QLQ FA13 (range 0--100) module, encompassing 13 items and five scales for measuring cancer-related fatigue \[[@B29-cancers-11-01771]\], with subscales covering physical fatigue, emotional fatigue, cognitive fatigue, interference with daily life, and social sequelae. Emotional distress was assessed using the QSC-R10 (range 0--50) questionnaire, which is a reliable questionnaire for determining emotional distress and anxiety in cancer patients \[[@B30-cancers-11-01771]\].

2.4. Statistical Analysis {#sec2dot4-cancers-11-01771}
-------------------------

Owing to the exploratory nature of this trial and lack of literature-based reference values, a complete power calculation was not possible; however, with 30 patients in each group, it was possible to detect a standardized mean-value effect of 0.8 with 80% power at a significance level of 0.05 \[[@B24-cancers-11-01771]\].

All statistical analyses were done using SAS software Version 9.4 or higher (SAS Institute, Cary, NC, USA). All variables were analyzed descriptively by tabulation of the measures of the empirical distributions. According to the scale level of the variables, means and standard deviations (SD) or absolute/relative frequencies, respectively, were reported. Additionally, for variables with longitudinal measurements, the time courses of individual patients were summarized by treatment groups. Descriptive *p*-values of the corresponding statistical tests comparing the treatment groups were reported. The VAS was adjusted for concurrent medications. Analysis of covariance (ANOVA) with repeated measurements, with treatment group as a factor, and pain medication as a covariate, were done. The Wilcoxon signed-rank test was used to detect possible differences between groups after 3 and 6 months. Graphical visualization includes the mean course over time. Finally, we compared the groups for overall survival, using Kaplan--Meier estimates and log-rank tests. Overall survival (OS) was defined as time from randomization until death, or censored at last contact.

3. Results {#sec3-cancers-11-01771}
==========

3.1. Patient Details {#sec3dot1-cancers-11-01771}
--------------------

Sixty patients were randomized, and 56 patients started on protocol-based management ([Figure 1](#cancers-11-01771-f001){ref-type="fig"}). One patient (CON) was removed for rapid clinical deterioration from cancer progression, one (INT) for new-onset jugular vein thrombosis, one (INT) for withdrawal of consent, and the final (INT) for severe motion-dependent therapy-resistant pain symptoms.

Baseline characteristics were balanced between the two arms ([Table 1](#cancers-11-01771-t001){ref-type="table"}). Most patients had thoracic spine disease, and statistical similarities were noted regarding the location of distant metastases, oncologic therapy, and pain medication utilization (*p* \> 0.20 for all). Of note, ten patients in the INT cohort and 14 subjects in the CON group initially wore an orthopedic corset (*p* = 0.396). Additionally of note, the Spinal Neoplastic Instability Score (SINS) \[[@B3-cancers-11-01771]\] in INT was significantly higher as compared to CON (12.0 vs. 10.3, *p* = 0.007), whereas the Mizumoto score was similar (5.0 vs. 5.5, *p* = 0.260).

The median follow-up was not yet achieved in both arms. Eleven patients (40.7%) in the INT group died of disease within three months of RT, versus six patients (20.7%) in the CON group. The mean OS was 4.4 months for both groups (*p* = 0.839) ([Figure 2](#cancers-11-01771-f002){ref-type="fig"}).

3.2. Tolerance of Therapy/Feasibility {#sec3dot2-cancers-11-01771}
-------------------------------------

RT was altogether tolerated well. No patient in either arm experienced grade ≥3 acute or late events according to the Common Terminology Criteria for Adverse Events v.4.03.

During the supervised training (t~0~--t~1~) there were no adverse events with protocol therapy. In the CON arm, 16 patients (55%) completed ≥80% of the planned relaxation sessions; the remainder were unable owing to deterioration in the general condition or clinical (non-protocol-related) complications. In INT, 18 (67%) patients completed ≥80% of the planned training sessions. The mean total number of completed training units was 7.8 (SD 3.3), and the mean number of potentially feasible units was 10.1 (SD 2.1).

Similarly, no adverse side effects were reported during post-radiotherapy home-based training (t~1~--t~2~). The specified number of home training sessions was 36 (3× weekly over 12 weeks). In the INT arm, 14 participants were lost to follow-up during the period of t~1~--t~2~; of these subjects, 11 died and 3 were unknown. From t~1~ to t~2~, ≥80% of planned sessions were completed by 64% (9/14) of patients. In INT, 14 analyzed participants completed 39.6 (SD 21.1) of the prescribed 36 training sessions.

3.3. Pain Response {#sec3dot3-cancers-11-01771}
------------------

No difference in pain response was observed between the two groups after 3 and 6 months ([Table 2](#cancers-11-01771-t002){ref-type="table"}).

There were also no differences in OMED consumption at the end of RT (t~1~) (*p* = 0.958) and three months (t~2~) following RT (*p* = 0.666). There were no statistical differences in neuropathic pain between both arms at 3 (*p* = 0.826) or 6 months (*p* = 0.965).

The covariance analysis of the OMED consumption in the period t~0~--t~2~ showed no significant influence on pain level (*p* = 0.120). The covariate evaluation of the interaction between group and time showed no significance, because the temporal changes were parallel (*p* = 0.970). Also, the group effect was not significant (*p* = 0.316). The pain response in the period t~0~--t~2~ showed a clear temporal dependence (*p* = 0.009) ([Figure 3](#cancers-11-01771-f003){ref-type="fig"}).

3.4. Bone Density and Pathologic Fractures {#sec3dot4-cancers-11-01771}
------------------------------------------

There were no differences in bone density between arms at 3 (*p* = 0.826) or 6 months following RT completion (*p* = 0.965). Within the CON group, from t~0~ to t~2~ there was a significant increase in bone density (*p* = 0.006) ([Table 3](#cancers-11-01771-t003){ref-type="table"}).

At initial presentation, there was a trend towards more pathologic fractures in the INT arm (n = 17, 63% vs. CON: n = 11, 39%, *p* = 0.079). No pathologic fractures in either arm were de novo; 1/14 and 3/18 cases were progressive in INT and CON, respectively (*p* = 0.419). There were no differences at 6 months (*p* = 0.243). Of note, no cases of salvage surgery for pathologic fractures were necessary in either arm.

Additionally, there did not seem to be differences in 3-month pathologic fractures based on use of an orthopedic corset (31% vs. 35%, *p* = 0.673).

3.5. Quality of Life {#sec3dot5-cancers-11-01771}
--------------------

In the INT group, the QOL parameter specifically for contemplation of painful sites had improved from initial presentation to the end of RT (*p* = 0.050), with a further positive trend between 3 and 6 months (*p* = 0.057). However, there was no evidence of treatment effect between t~0~--t~2~ (*p* = 0.478) or t~0~--t~3~ (*p* = 0.753) ([Table 4](#cancers-11-01771-t004){ref-type="table"}, [Table 5](#cancers-11-01771-t005){ref-type="table"} and [Table 6](#cancers-11-01771-t006){ref-type="table"}).

At all recorded time points, there were no significant QOL differences between groups, including pain characteristics, functional impairment, or psychosocial aspects (*p* \> 0.05 for all). There were also no differences in all dimensions of fatigue between groups at each recorded time point (*p* \> 0.05 for all). Emotional distress was also similar (*p* = 0.235).

4. Discussion {#sec4-cancers-11-01771}
=============

The safety and feasibility of IPMT to better address pain, mobility, and QOL has heretofore never been prospectively addressed in patients with USM, who are at high risk of clinical exacerbation from such interventions. From this exploratory randomized study, the first of its kind to date, IPMT is potentially feasible for this high-risk population, with a clear majority of patients being able to complete the assigned regimen. During the observation period, in the INT group no serious side effects occurred requiring surgical intervention. However, the conclusion about the safety of IPMT can only be made with restrictions, given the high percentage of patients lost to follow-up or death.

It should first be addressed that this study was not powered to evaluate secondary endpoints such as pain response, bone density, pathologic fracture rate (which was imbalanced at baseline), and QOL. Hence, the statistically equivocal results in most of these parameters cannot be used to conclude that IPMT offers no benefit as compared to passive muscle relaxation. Rather, this study demonstrates its safety and feasibility, in efforts to further utilize this regimen in larger studies to adequately test other such endpoints.

This being said, pain response may be less impacted by IPMT and more by RT technique, as shown in promising randomized trials of ablative versus fractionated RT \[[@B31-cancers-11-01771],[@B32-cancers-11-01771]\]. Herein, merging both 3DCRT and IMRT cases would not be expected to confound results, as both are fractionated and do not display differences in relevant endpoints. Bone density changes generally do not occur acutely and may also be impacted by other factors such as the short duration of follow-up herein.

The covariate analysis of pain response during t0--t2 showed no influence of OMED on VAS values in the INT group (*p* = 0.120). However, within the time period t0--t2, pain response within that group was clearly evident (*p* = 0.009). Similarly, examination of the supervised training units from t~0~ to t~1~ showed significant pain relief (*p* \< 0.001, data not shown).

Despite the numerically increased initial fracture rate in the INT arm (n = 17, 63% vs. CON: n = 11, 39%, *p* = 0.079) (which also had statistically higher SINS scores at baseline), no *de novo* fractures occurred. Only existing fractures showed a visible increase in INT (1/14 cases) and CON (3/18) (*p* = 0.419).

Future studies should stratify groups according to fracture rate at baseline or SINS score to avoid imbalance between groups. Importantly, the numerically higher pathologic fracture rate in INT at baseline did not translate to appreciable QOL changes, which is noteworthy. Lastly, it is also relatively intuitive that there were largely no significant QOL differences between arms, as QOL is a complex outcome that depends on a multitude of factors such as systemic disease status, ongoing therapies, and baseline functionality. It is thus likely that effects on QOL by IPMT (if present) would be blurred between cohorts based on other factors known to contribute to QOL.

The utility of this investigation impacts future studies in patients with spinal metastases. Historically, patients with stable spine metastases were often restricted from such activities, with even tighter restrictions in USM cases. In the more recent era, many protocols do not specify whether these exercise regimens are allowed. For instance, the RTOG 0631 protocol does not make a specific recommendation on this matter. Although that study pertains to SBRT instead of a traditional 5--10 fraction regimen as utilized herein, further work must be done to verify whether IPMT is safe for well-selected USM cases undergoing SBRT (recognizing that many will not be able to receive SBRT for several reasons).

The difficulty of planning a fixed number of training sessions in the palliative setting is well acknowledged, and as a result there was no precedent to how many high-risk USM patients could complete these sessions. This was a major reason why this randomized trial was exploratory in nature and why formal power calculations could not be made. All patients herein experienced systemic progression at some point during follow-up, which (along with side effects of therapy in itself) often requires temporary or prolonged stationary accommodation and may not be conducive to continuing the training program.

In addition to the above, there are several limitations meriting elaboration. Along with the small sample sizes, short follow-up/patient survival, and single-center nature, studies of the palliative population encompass inherently heterogeneous patients, and the effect on subgroups thus cannot be reliably analyzed. This also makes the results difficult to extrapolate to other work, along with the fact that the particular assessment methods (e.g., VAS) and frequencies thereof may differ from other work, hence also limiting generalizability. Second, corticosteroid doses were not accounted for, which may impact pain levels and "pain flares". Third, reasons for opioid usage as well as subjective pain relief are inherently difficult to assess, and are known limitations of any palliative study despite the prospective nature. Fourth, because the patients were included with a Karnofsky index \>70%, it may not necessarily include a representative population reflective of clinical practice. Nevertheless, these shortcomings do not diminish the requirement to construct similar randomized trials powered for other endpoints, especially given that the safety and feasibility of IPMT in the high-risk USM population has been supported by these randomized results.

5. Conclusions {#sec5-cancers-11-01771}
==============

IPMT is potentially feasible for high-risk USM patients. Future trials adequately powered for relevant endpoints are thus recommended.
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cancers-11-01771-t001_Table 1

###### 

Demographics. Baseline characteristics of randomly assigned participants.

                                            Intervention Group n = 27   Control Group n = 29   *p*-Value              
  ----------------------------------------- --------------------------- ---------------------- ------------- -------- -------
  Age (years, mean SD)                      62.1 (8.8)                                         61.1 (8.5)             0.724
  *Gender*                                                                                                            0.611
  Male                                      13                          48.1                   12            41.4     
  Female                                    14                          51.9                   17            58.6     
  Weight (kg, mean SD)                      71.5 (11.3)                                        75.1 (15.4)            0.337
  Height (cm, mean SD)                      172.2 (8.6)                                        170.4 (9.0)            0.426
  Body mass index (BMI, mean SD, kg/m^2^)   24.4 (4.1)                                         25.8 (4.6)             0.260
  *Primary site*                                                                                                      0.654
  Lung cancer                               8                           29.6                   14            48.3     
  Breast cancer                             7                           25.9                   6             20.7     
  Prostate cancer                           4                           14.8                   2             6.9      
  Other                                     8                           29.7                   3             24.1     
  *Localization metastases*                                                                                           0.423
  Thoracic                                  20                          74.1                   24            82.8     
  Lumbar                                    7                           25.9                   5             17.2     
  *Distant metastases at baseline*                                                                                    
  Viszeral                                  9                           33.3                   13            44.8     0.379
  Lung                                      5                           18.5                   11            37.9.1   0.108
  Brain                                     7                           25.9                   5             17.2     0.423
  Soft tissue                               2                           7.4                    7             24.1     0.089
  Hormontherapy                             9                           33.3                   6             20.7     0.286
  Immunotherapy                             12                          44.4                   13            44.8     0.977
  Chemotherapy                              19                          70.4                   21            72.4     0.866
  Surgery                                   15                          55.6                   12            41.4     0.289
  Bisphosphonate at baseline                11                          40.7                   14            48.3     0.571
  Orthopedic corset at baseline             10                          37.0                   14            48.3     0.396
  Mizumoto-Score (mean, SD)                 5.0 (2.0)                                          5.5 (1.7)              0.260
  SINS-Score (mean, SD)                     12.0 (2.5)                                         10.3 (2.2)             0.007
  *Medication at baseline*                                                                                            
  Sleeping medication                       4                           14.8                   9             31.0     0.151
  Psychiatric medication                    8                           29.6                   8             27.6     0.866
  Dexamethasone                             5                           18.5                   2             6.9      0.189
  Opiate                                    15                          55.6                   16            55.2     0.977
  NSAID                                     20                          74.1                   22            75.9     0.877
  Inpatient stay                            13                          48.1                   11            37.9     0.440

Abbreviation: *SD*: standard deviation; *SINS*: spinal instability neoplastic score; *others*: adenoid cystic carcinoma, carcinoma of unknown primary (CUP), gastrointestinal stroma tumor (GIST), melanoma, mesothelioma, pancreatic cancer, renal cancer, thyroid cancer, urothelial carcinoma.

cancers-11-01771-t002_Table 2

###### 

Pain levels using the Visual Analogue Scale (VAS) at respective points in time of survey in both groups.

                             Intervention Group n = 27          Control Group n = 29   *p*-Value          
  --------------------- ---- --------------------------- ------ ---------------------- ----------- ------ -------
  VAS                   n    mean                        SD     n                      mean        SD     
  Baseline              27   41.3                        29.6   29                     44.3        29.3   0.665
  End of radiotherapy   26   30.6                        19.7   29                     29.1        24.8   0.659
  3 months              14   25.4                        15.5   18                     28.3        26.6   1.000
  6 months              7    24.3                        18.1   9                      25.0        26.1   0.830

Abbreviation: *VAS*: visual analog scale.

cancers-11-01771-t003_Table 3

###### 

These results demonstrate the bone density (HU = Hounsfield units) in metastatic bone before RT (baseline), three and six months after RT. The results were presented by absolute and relative values (%) of HU within and between group as median (Hodges--Lehmann estimate) and IQR.

                             Intervention Group           Within Group   Control Group                Within Group   Differences between Groups                           
  -------------------------- -------------------- ------- -------------- --------------- ---- ------- -------------- ---------------------------- ------- --------------- -------
  *All metastases*                                                                                                                                                        
  HU Baseline                25                   200.0   136.0--240.0                   29   168.0   139.0--268.0                                −3.0    −57.0--47.0     0.903
  HU T2                      13                   278.0   215.0--380.0                   18   219.5   137.0--385.0                                47.5    −63.0--150.0    0.378
  HU T3                      8                    364.0   237.0--364.0                   10   348.5   217.0--478.0                                9.0     −144.0--160.0   0.756
  *3 months*                                                                                                                                                              
  HU T0--T2                  13                   1.00    −18.0--190.0   0.350           18   30.5    −9.0--70.0     0.101                        5.5     −48.0--154.0    0.826
  HU T0--T2 (%)              13                   0.38    −7.5--118.0    0.491           18   19.0    −7.3--31.7     0.060                        3.2     −26.0--82.1     0.674
  *6 months*                                                                                                                                                              
  HU T0--T3                  8                    111.5   −23.5--268.5   0.219           10   99.5    69.0--175.0    0.006                        −2.0    −137.0--190.0   0.965
  HU T0--T3 (%)              8                    67.8    −9.0--139.5    0.219           10   49.8    19.4--118.2    0.004                        −0.2    −68.7--14.9     0.964
  *Subgroup analysis*                                                                                                                                                     
  *Osteolyltic metastases*                                                                                                                                                
  HU Baseline                10                   128.5   108.0--192.0                   15   153.0   124.0--173.0                                −17.5   −59.0--32.0     0.506
  HU T2                      4                    268.0   160.5--365.5                   6    196.0   112.0--238.0                                56.5    −210.0--268.0   0.749
  HU T3                      3                    380.0   136.0--384.0                   5    237.0   217.0--323.0                                57.0    −238.0--178.0   0.551
  *3 months*                                                                                                                                                              
  HU T0--T2                  4                    95.0    −7.5--224.5    0.500           6    32.0    −31.0--43.0    0.469                        81.5    −70.0--290.0    0.456
  HU T0--T2 (%)              4                    59.0    −3.7--166.0    0.500           6    25.4    −7.3--33.3     0.312                        53.6    −41.7--221.3    0.594
  *6 months*                                                                                                                                                              
  HU T0--T3                  3                    223.0   0.0--259.0     0.500           5    78.0    69.0--122.0    0.125                        101.0   −175.0--311.0   0.371
  HU T0--T3 (%)              3                    138.5   0.0--214.0     0.500           5    56.1    41.1--118.2    0.125                        68.8    −145.2--226.3   0.551
  *Mixed metastases*                                                                                                                                                      
  HU Baseline                15                   230.0   186.0--261.0                   14   252.5   165.0--349.0                                25.5    −52.0--116.0    0.513
  HU T2                      9                    278.0   222.0--448.0                   12   317.0   148.5--432.5                                44.5    −127.0--162.0   0.696
  HU T3                      5                    348.0   247.0--483.0                   5    478.0   376.0--524.0                                −41.0   −277.0--158.0   0.834
  *3 months*                                                                                                                                                              
  HU T0--T2                  9                    1.00    −18.0--187.0   0.476           12   16.0    −7.0--107.5    0.266                        −9.0    −79.0--163.0    0.804
  HU T0--T2 (%)              9                    0.38    −7.7--71.6     0.652           12   7.9     −5.6--31.4     0.204                        0.6     −31.3--72.0     0.972
  *6 months*                                                                                                                                                              
  HU T0--T3                  5                    −15.0   −32.0--278.0   0.812           5    114.0   85.0--260.0    0.062                        −82.0   −310.0--227.0   0.531
  HU T0--T3 (%)              5                    −5.7    −12.4--135.6   0.812           5    43.5    19.4--115.6    0.062                        −31.7   −128.2--116.2   0.676

Abbreviations: HU = Hounsfield units, IQR = interquartile range, T~0~ = baseline, T~2~ = 3 months, T~3~ = 6 months, T~0~--T~2~ = difference baseline minus 3 months, T~0~--T~3~ = difference baseline minus 6 months. HL = Hodges-Lehmann estimator, 95% CI = 95% Confidence Interval.
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###### 

Effects on QOL (EORTC QLQ-BM 22) questionnaire.

  Symptom Scales                                                                                                             
  ------------------------------------------------------------------------------------------- ---- ------ ------ ---- ------ ------
  **Painful sites**                                                                           n    mean   SD     n    mean   SD
  End of radiotherapy (t1)                                                                    26   29.5   19.5   29   20.7   20.3
  3 months (t2)                                                                               14   27.6   19.9   18   22.2   13.9
  6 months (t3)                                                                               7    32.4   18.4   9    17.8   14.1
  Treatment effect (t0--t2) after 3 months *p* = 0.478, (t0--t3) after 6 months *p* = 0.753                                  
  Effect size (t0--t2) after 3 months −5.9, (t0--t3) after 6 months 4.7                                                      
  **Pain characteristics**                                                                                                   
  End of radiotherapy (t1)                                                                    26   44.9   28.4   29   36.0   32.6
  3 months (t2)                                                                               14   30.2   28.7   18   29.5   28.3
  6 months (t3)                                                                               7    22.2   22.2   9    23.5   26.3
  Treatment effect (t0--t2) after 3 months *p* = 0.813, (t0--t3) after 6 months *p* = 0.470                                  
  Effect size (t0--t2) after 3 months −2.6, (t0--t3) after 6 months −10.8                                                    
  **Functional interference**                                                                                                
  End of radiotherapy (t1)                                                                    26   44.6   24.6   29   36.2   22.6
  3 months (t2)                                                                               14   37.8   29.3   18   28.5   18.7
  6 months (t3)                                                                               7    28.6   26.8   9    31.9   19.8
  Treatment effect (t0--t2) after 3 months *p* = 0.611, (t0--t3) after 6 months *p* = 0.269                                  
  Effect size (t0--t2) after 3 months −3.8, (t0--t3) after 6 months −9.9                                                     
  **Psychosocial aspects**                                                                                                   
  End of radiotherapy (t1)                                                                    26   58.5   17.5   29   50.4   18.1
  3 months (t2)                                                                               14   52.4   20.8   18   52.2   18.6
  6 months (t3)                                                                               7    42.9   23.3   9    51.2   21.5
  Treatment effect (t0--t2) after 3 months *p* = 0.072, (t0--t3) after 6 months *p* = 0.348                                  
  Effect size (t0--t2) after 3 months −15.2, (t0--t3) after 6 months −7.2                                                    
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###### 

Effects on fatigue according to EORTC QLQ-FA 13 questionnaire.

                                                                                              Intervention Group   Control Group                      
  ------------------------------------------------------------------------------------------- -------------------- --------------- ------ ---- ------ ------
  **Physical fatigue**                                                                        n                    mean            SD     n    mean   SD
  End of radiotherapy (t1)                                                                    25                   60.0            25.1   29   52.0   28.9
  3 months (t2)                                                                               14                   45.2            31.0   18   50.0   28.7
  6 months (t3)                                                                               7                    45.2            34.6   9    46.3   30.1
  Treatment effect (t0--t2) after 3 months *p* = 0.06, (t0--t3) after 6 months *p* = 0.06                                                             
  Effect size (t0--t2) after 3 months −16.2, (t0--t3) after 6 months −16.2                                                                            
  **Emotional fatigue**                                                                                                                               
  End of radiotherapy (t1)                                                                    25                   39.7            30.0   29   29.9   28.3
  3 months (t2)                                                                               14                   27.4            23.7   18   31.5   30.2
  6 months (t3)                                                                               7                    31.0            39.9   9    30.6   30.3
  Treatment effect (t0--t2) after 3 months *p* = 0.056, (t0--t3) after 6 months *p* = 0.928                                                           
  Effect size (t0--t2) after 3 months−18.6, (t0--t3) after 6 months −1.6                                                                              
  **Cognitive fatigue**                                                                                                                               
  End of radiotherapy (t1)                                                                    25                   17.3            18.7   29   13.0   16.8
  3 months (t2)                                                                               14                   16.7            16.2   18   13.0   18.4
  6 months (t3)                                                                               7                    23.8            37.1   9    13.6   12.1
  Treatment effect (t0--t2) after 3 months *p* = 0.117, (t0--t3) after 6 months *p* = 0.440                                                           
  Effect size (t0--t2) after 3 months −10.8, (t0--t3) after 6 months 6.9                                                                              
  **Interference with daily life**                                                                                                                    
  End of radiotherapy (t1)                                                                    25                   50.7            37.4   29   41.4   29.1
  3 months (t2)                                                                               14                   50.0            36.4   18   28.9   30.8
  6 months (t3)                                                                               7                    42.9            41.8   9    29.6   35.1
  Treatment effect (t0--t2) after 3 months *p* = 0.780, (t0--t3) after 6 months *p* = 0.230                                                           
  Effect size (t0--t2) after 3 months −2.9, (t0--t3) after 6 months 16.9                                                                              
  **Social sequelae**                                                                                                                                 
  End of radiotherapy (t1)                                                                    25                   14.7            23.7   29          
  3 months (t2)                                                                               14                   16.7            28.5   18          
  6 months (t3)                                                                               7                                           9           
  Treatment effect (t0--t2) after 3 months *p* = 0.936, (t0--t3) after 6 months *p* = 0.366                                                           
  Effect size (t0--t2) after 3 months 0.79, (t0--t3) after 6 months 12.2                                                                              
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###### 

Effects on emotional distress according to FBK-R10 questionnaire.

                                                                             Intervention Group                Control Group          
  -------------------------------------------------------------------------- -------------------- ------ ----- --------------- ------ -----
  **FBK R10**                                                                n                    mean   SD    n               mean   SD
  Baseline (t0)                                                              26                   23.7   8.5   29              17.9   9.2
  End of radiotherapy (t1)                                                   26                   19.7   8.5   28              15.7   8.6
  3 months (t2)                                                              14                   19.7   9.3   18              13.8   9.4
  Treatment effect (t0--t2) after 3 months between the groups *p* = 0.235,                                                            
  Effect size (t0--t2) after 3 months −4.1                                                                                            
